Searching for a common mechanism for placenta mediated pregnancy complications and cardiovascular disease: role of Lipoprotein (a) by Romagnuolo, Ilaria et al.
 1 
                                                                                                 “ F & S_FandS21058R1” 1 
Running title: Lp(a) in obstetric and vascular disease               2 
Title: Searching for a common mechanism for placenta mediated pregnancy 3 
complications and cardiovascular disease: role of Lipoprotein (a) 4 
 5 
Ilaria Romagnuoloa,* MSc, Elena Sticchib MSc,PhD, Monica Attanasio a,b MSc, Elisa Grifonia 6 
MD, Gabriele Cionia MD PhD,  Anna Paola Cellaib MSc, Rosanna Abbatea,b Full Professor, 7 
Cinzia Fatinia,b MD, PhD 8 
 9 
a University of Florence, Department of Experimental and Clinical Medicine,  Thrombosis 10 
Centre, Largo Brambilla, 3  50134, Florence, Italy. 11 
b Department of Heart and Vessels, Thrombosis Centre, Azienda Ospedaliero-Universitaria 12 
Careggi, Largo Brambilla, 3  50134, Florence, Italy. 13 
 14 
* Corresponding Author: 15 
Cinzia Fatini, MD PhD 16 
Department of Experimental and Clinical Medicine, Thrombosis Centre, University of 17 
Florence, Florence, Italy;  18 
email: cinzia.fatini@unifi.it 19 
phone: +39 055-7949420;  20 
Fax: +39 055-7949929 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 2 
Capsule: This study shows an association between Lp(a) concentrations and history of 1 
Stillbirth and Preeclampsia; this well-known atherothrombotic marker might represent one of 2 
the mechanisms shared by obstetric and cardiovascular disease. 3 
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Abstract 1 
Objective: To investigate Lipoprotein (a) [Lp(a)], a well-know cardiovascular risk factor, in 2 
women with history of placenta mediated pregnancy complications (PMPC) compared with 3 
healthy uneventful pregnancy women (HW), and the role of LPA functional polymorphisms 4 
in modulating both Lp(a) levels and PMPC risk. 5 
Design: Retrospective, observational study . 6 
Setting: Gender Medicine Clinic, Centre for Atherothrombotic Disease, University Hospital. 7 
Patients: 360 women with history of PMPC [154 preeclampsia (PE), 121 stillbirth (SB), 85 8 
small for gestational age (SGA)] and in 270 HW.  9 
Intervention(s): None 10 
Main Outcome Measure(s): Lp(a) levels measurement and LPA +93C>T and +121G>A  11 
polymorphisms genotyping. 12 
Results: In PMPCs we observed higher Lp(a) levels than those found in HW, and an 13 
association with PMPC risk [OR= 1.93 (1.20-3.09)], also after adjustment for age, familial 14 
history of cardiovascular disease, and traditional risk factors. By analyzing Lp(a) 15 
concentrations according to each pregnancy complication, we observed significantly higher 16 
Lp(a) levels in women with history of SB and PE, conferring a 2.5-fold and a 2-fold increased 17 
risk, respectively; no association with SGA was observed. Lp(a) concentrations progressively 18 
and significantly increased as LPA unfavorable allelic burden increased; unfavorable allelic 19 
burden influenced  SB and PE risk. 20 
Conclusions: We evidenced, for the first time, an association between high Lp(a) 21 
concentrations and history of SB, and we confirmed the role of Lp(a) in PE risk; this well-22 
known atherothrombotic marker might represent one of the possible mechanisms shared by 23 
PMPC and cardiovascular disease.  24 
Key-words: Lipoprotein(a), Stillbirth, Preeclampsia, LPA gene. 25 
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Introduction 1 
Data from literature evidenced that a history of placenta mediated pregnancy complications 2 
(PMPC) such as preeclampsia, small for gestational age neonate, and stillbirth increased risk 3 
of cardiovascular disease (CVD) later in life (1,2), and entered as major risk factor for CVD 4 
in the AHA/ASA guidelines (3,4). 5 
There is a common pathophysiologic pathway of endothelial dysfunction linking placental 6 
and vascular disorders. Beyond traditional cardiovascular risk factors, there is a wide variety 7 
of cardiovascular biomarkers endothelial dysfunction-related, which are still not widely 8 
explored in the clinical studies, such as lipoprotein (a) [Lp(a)]. Lipoprotein(a) is a plasma 9 
lipoprotein composed of a LDL particle and an additional lipoprotein, apolipoprotein(a), 10 
linked to apo B 100 of the LDL (5). Lp(a) plays a relevant role in the development of 11 
atherosclerosis, through multiple pathways, such as Lp(a)-derived cholesterol entrapment in 12 
the intima, inflammatory cell recruitment, and binding of pro-inflammatory-oxidized 13 
phospholipids to endothelial cells (6,7). Lp(a) also contributes to a prothrombotic phenotype 14 
through antifibrinolytic actions (8), due to its high homology to plasminogen, and to the 15 
inhibition of tissue factor pathway inhibitor. 16 
Data from literature provided evidence that elevated Lp(a) concentrations represent an 17 
independent risk factor for premature cardiovascular disease (9-11). 18 
Lp(a) concentrations are under genetic control at the concentration of biosynthesis of the 19 
apo(a) protein, which is encoded by the LPA locus; allelic differences at LPA locus may be 20 
responsible for the variations in Lp(a) phenotype (12). Variants at LPA locus have been 21 
associated with both an increased levels of Lp(a) and an increased risk of coronary disease 22 
(11). 23 
The role of Lp(a) in pregnancy complications has been object of some clinical studies 24 
reporting not definite results (13). Few studies evaluate the relationship between Lp(a) and 25 
 5 
preeclampsia (14, 15), only one study explored its role in affecting small for gestational age 1 
predisposition (15), but, at the best of our knowledge, no study is available concerning the 2 
influence of Lp(a) in modulating stillbirth risk. 3 
In this scenario we investigated Lp(a) in women with history of stillbirth, preeclampsia or 4 
small for gestational age neonate in order to evaluate the role of this well-known 5 
atherothrombotic marker in obstetric negative outcome risk; we also investigated the role of 6 
LPA functional polymorphisms in modulating both Lp(a) levels and PMPC risk. 7 
 8 
Methods 9 
Study population 10 
The entire study population comprised 870 consecutive women referred to Gender Medicine 11 
Clinic of the Center for Atherothrombotic Disease, Department of Experimental and Clinical 12 
Medicine, University Hospital, Florence, from 2010 to 2013, in order to be framed for 13 
vascular risk. 14 
In Supplemental Figure 1 the study population is reported. Three hundred and sixty women 15 
with history of pregnancy complications related to uteroplacental vascular insufficiency 16 
(PMPC) [154 with history of preeclampsia (PE), 121 stillbirth (SB), 85 small for gestational 17 
age (SGA) neonates] were referred from gynecologists to Gender Medicine Clinic in order to 18 
be framed for their cardiovascular risk, as history of placenta mediated pregnancy 19 
complications represents a new cardiovascular risk factor; information concerning the adverse 20 
obstetrical outcomes derived from written gynecologists’ clinical report (PE defined as 21 
systolic blood pressure >140 mmHg or diastolic blood pressure ≥90 mmHg and 24-hour 22 
proteinuria ≥0.3 g; SB defined as late intrauterine fetal death after 24 completed weeks of 23 
pregnancy; SGA defined as infant born with a birth weight less than the 10th centile, 24 
according to RCOG guidelines). 25 
 6 
Two hundred and seventy healthy women (HW) with no history of vascular disease, referred 1 
to Gender Medicine Clinic for evaluating thrombotic risk before taking estrogen-progesterone 2 
therapy or for family history of vascular disorders were considered as controls. These women 3 
delivered after uneventful pregnancy. In order to identify disease free controls, and to exclude 4 
women who were thought to have any form of vascular disease, a detailed interview 5 
addressing personal and familial history was performed. All women were investigated for 6 
Lp(a) after a minimum of 12 weeks postpartum. None were pregnant or had use oral 7 
contraceptive for at least 8 weeks before testing. 8 
Exclusion criteria were the presence of diabetes mellitus, renal failure, pregnancy 9 
complications explained by anatomic, chromosomal, endocrine or immunological 10 
abnormalities, or intercurrent infectious events. Non-Caucasian origin (primarily because of 11 
the difference in the prevalence of the genetic polymorphisms) represented a further exclusion 12 
criterium. Finally, women who refused to assent with the genetic analysis were not included.  13 
Informed written consent for anonymous data analysis was obtained from all women and the 14 
study was approved by the local Ethical Review Board. The investigation conforms with the 15 
principles outlined in the Declaration of Helsinki.  16 
Genotyping 17 
Genomic DNA was isolated from peripheral blood leukocytes by using GeneCatcher™ 18 
gDNA Blood Kit (Invitrogen) with the aid of automated platform Freedom EVO 150 (Tecan).  19 
LPA +93C>T (rs1853021) and +121G>A (rs1800769) polymorphisms have been detected 20 
with PCR-RFLP analysis. The sequence surrounding the two SNPs has been amplified 21 
through PCR reaction with the following settings: one denaturation cycle at 95 °C for 5′, 35 22 
cycles with denaturation at 94 °C for 1′, annealing at 54 °C for 50″ and extension at 72 °C for 23 
50″, followed by a final extension at 72 °C for 7’. The reaction has been performed in a final 24 
volume of 25 μl with 100 ng of genomic DNA, 0.2 mM of each dNTP, 1 μl of a 10 μM 25 
 7 
forward primer (5′-TGACATTGCACTCTCAAATATTTT-3′), 1 μl of a 10 μM reverse 1 
primer (5′- AGAACCACTTCCTTATGTTCCA-3′) and 0.5 U of Taq polymerase (GoTaq, 2 
Promega Italia, Milano, Italy) in 1× PCR Buffer. 3 
In order to detect LPA +93C>T SNP, 10 μl of the PCR products (222 bp) are subjected to 4 
digestion with TaiI restriction enzyme (Fermentas International Inc., Burlington, Canada) 5 
while the evaluation of LPA+121G>A transition requires an enzymatic digestion with SduI 6 
(Fermentas International Inc., Burlington, Canada). Both the reactions are carried out at 37 °C 7 
for 16 h and the digestion fragments are separated on 3.5% agarose gel. 8 
Lipoprotein (a) measurements 9 
Blood samples were collected from the antecubital vein into evacuated plastic tubes 10 
(Vacutainer), after an overnight fast. Sera samples were obtained by centrifuging blood 11 
collected in evacuated tubes without anticoagulant at 2000×g for 10 min at 4 °C, subsequently 12 
stored at −20 °C. Lp(a) levels were detected by an immune-nephelometry method on serum 13 
samples through the use of the LPAX reagent in conjunction with IMMAGE800 14 
Immunochemistry Systems and Lipoprotein(a) Calibrator (Beckman Coulter, Milan, Italy). 15 
The cut-off for this analyte is represented by values equal to 300 mg/l which represented an 16 
independent risk factor for vascular disease (16, 17). Intra-assay and inter-assay coefficients 17 
of variation were <5%. 18 
Statistical analysis  19 
Few data are available concerning Lp(a) levels in women with history of obstetric events (14); 20 
these studies documented a prevalence of high Lp(a) levels of about 30% and 10% in women 21 
with history of obstetric events and uneventful pregnancy, respectively. Based on this 22 
observation, a sample size of at least 100 women for each group was deemed sufficient to 23 
prove/exclude an association between high Lp(a) levels and placenta mediated pregnancy 24 
complications with a statistical power of 90% (β) and a significance value of 5% (α). 25 
 8 
Statistical analyses were performed using the SPSS software (Chicago, IL, USA) for 1 
Windows (Version 11.5). 2 
Age was expressed as median (range), and the categorical variables were expressed as 3 
frequencies and percentages. The only continuous variable which shows a normal distribution 4 
(age) was analyzed by using a parametric test (t-Student test); the nonparametric Mann–5 
Whitney test for unpaired data was used for comparisons of the other continuous variables 6 
between single groups. Chi-square test was used to test for proportions and for deviation of 7 
genotype distribution of LPA polymorphisms from the Hardy-Weinberg equilibrium. Because 8 
Lp(a) distribution was right-skewed, values were log-transformed in regression analyses and 9 
back transformed for data presentation. A logistic regression analysis was used in order to 10 
evaluate the role of Lp(a) levels in modulating pregnancy complications risk. Variables which 11 
showed, at univariate analysis, a significant association with the disease were introduced into 12 
the multivariate model, as well as age and smoking habits. During multivariate analysis, a 13 
first model (Model 1) was created by adjusting for age and familial history of cardiovascular 14 
disease; subsequently, a second model (Model 2) was created by also adjusting for 15 
hypertension, dyslipidemia, smoking habit, and BMI>25 Kg/m2. Odds ratios and 95% 16 
confidence intervals are presented. A p-value less than 0.05 was considered to indicate 17 
statistical significance. 18 
In order to investigate the relationship between Lp(a) concentrations and LPA functional 19 
alleles, the study population was divided into five subgroups according to allelic burden: 20 
group 0 (women homozygous for LPA 120GG and 93TT), group 1 (women carrying one LPA 21 
functional variant related to increased gene expression), group 2 (women carrying two LPA 22 
functional variants related to increased gene expression),  group 3 (women carrying three 23 
LPA functional variants related to increased gene expression), and group 4 (women 24 
 9 
homozygous for LPA 120AA and 93CC). Kruskall–Wallis test was performed to compare 1 
Lp(a) concentrations among different groups of allelic burden. 2 
In order to evaluate the influence of allelic burden on pregnancy complications risk, a linear 3 
regression analysis was performed and results were expressed as regression coefficient 4 
(β)±SE.  5 
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Results 1 
Lipoprotein(a) concentrations and placenta mediated pregnancy complications 2 
Demographic, clinical and laboratory characteristics of the study population are reported in 3 
Table 1. A higher prevalence of hypertension, BMI>25 Kg/m2, dyslipidemia, and familial 4 
history of cardiovascular disease was observed in women with history of PMPC in 5 
comparison to that found in controls. By analyzing traditional cardiovascular risk factors 6 
according to each pregnancy complication, we observed a significantly higher prevalence of 7 
hypertension and BMI>25 Kg/m2  in women with history of SB and PE; with regard to lipid 8 
profile, higher percentage of dyslipidemic women in SB, PE and SGA group with respect to 9 
that observed in controls was found (Supplemetal Table 1). Lp(a) concentrations have been 10 
assessed between 12 to 25 weeks after delivery; a significant higher percentage of women 11 
with history of PMPC (31.9%) exhibited Lp(a) concentrations above 300 mg/L cut-off  12 
respect to that found in healthy controls (17.1%) (p< 0.0001) (Table 1). Higher Lp(a) 13 
concentrations in both patients and controls with familial history of CVD [338.2 (237.2-14 
440.1) and 205.9 (138.3-273.7), respectively] in comparison to those observed in patients and 15 
controls without familial history of CVD [253.4 (199.3-307.5) and 182.2 (154.2-210.2), 16 
respectively] were found.   17 
Patients with pregnancy complications were more likely to have cardiovascular risk factors 18 
which may represent confounders, therefore, we performed an additional analysis by 19 
excluding potential confounders such as smoking, chronic hypertension, BMI>30 Kg/m2 20 
dyslipidemia and familial history of CVD; our results evidenced a significantly higher Lp(a) 21 
conentrations in women with history of placenta mediated pregnancy complications in 22 
comparison to that observed in controls (Supplemental Table 2). 23 
When we analyzed Lp(a) concentrations according to each pregnancy complication (SGA, 24 
PE, SB), we observed a significantly higher Lp(a) levels in  women with history of SB and 25 
 11 
PE, whereas in women with history of SGA Lp(a) levels were higher, even if not 1 
significantly,  in comparison to those found in controls (Figure 1). 2 
In order to search a possible association between high Lp(a) levels and PMPC, we performed 3 
a logistic regression analysis, which showed a significant association between Lp(a) 4 
concentrations and obstetric negative outcomes [OR= 1.93 (1.20-3.09), p=0.006]; after 5 
adjustment for age and familial history of cardiovascular disease (Model 1), as well as for  6 
hypertension, smoking habit, BMI and dyslipidemia and timing from delivery (Model 2), high 7 
Lp(a) concentrations remained significantly associated with PMPC (Table 2); in particular, 8 
high Lp(a) levels conferred, a 2.5-fold increased risk of SB, and a 2-fold increased risk of PE, 9 
also after adjustment for Model 1 and Model 2.  No association between high Lp(a) levels and  10 
SGA was observed (Table 2).  11 
Because of its seems backwards to use Lp(a) measured after the obstetric complications to 12 
predict these negative outcomes, we performed a supplemental analysis in which Lp(a) 13 
concentrations are considered as the outcome. At linear regression analysis we observed a 14 
significant influence of a history of PMPC on Lp(a) concentrations (β =0.11±0.05; p = 0.04); 15 
in particular, both SB and PE significantly correlated with Lp(a) levels ((β =0.17±0.07; p = 16 
0.02,  β =0.14±0.06; p = 0.02, respectively). 17 
 18 
 19 
LPA polymorphisms and Lp(a) concentrations 20 
All subjects were genotyped for two LPA gene polymorphisms (LPA 93C>T and LPA 21 
121G>A); genotype distribution and allele frequencies were in agreement with those 22 
predicted by Hardy-Weinberg equilibrium. As concerns the LPA 121G>A polymorphism, 23 
women with history of PMPC exhibited a higher, even if not significantly, 121A allele 24 
 12 
frequency, in comparison to that observed in controls (0.12 vs 0.09, respectively); 93T allele 1 
frequency was comparable between patients and controls (0.13 vs 0.14, respectively). 2 
Due to the relatively small influence of each polymorphism on Lp(a) phenotype, we evaluated 3 
the weight of more than one unfavorable variant in influencing both Lp(a) concentrations and 4 
obstetric complications risk.  5 
Accordingly, we divided our study population in relation to allelic burden groups, and we 6 
observed that Lp(a) concentrations progressively and significantly increased as allelic burden 7 
increased (p=0.001) (Figure 2).   8 
As concerns the role of allelic burden in modulation obstetric complication risk, we 9 
performed a further analysis in order to investigate single allele or more than one 10 
unfavourable alleles role in influencing pregnancy negative events; at linear regression 11 
analysis a trend toward a significant influence of allelic burden on PE and stillbirth risk was 12 
observed (β =0.402±0.065; p = 0.06). 13 
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Discussion 1 
 2 
Our findings provided evidence that women with history of pregnancy complicated by SB 3 
exhibited high Lp(a) concentrations, beyond a high prevalence of cardiovascular risk factors, 4 
such as unfavorable lipid profile, high blood pressure and BMI >25 Kg/m2. These data could 5 
rekindle Lp(a) interest in relation to the history of obstetric complications, really the 6 
availability of new drugs which are showing novel therapeutic/safety profiles, could lead to 7 
introduce preventive strategies in clinical practice.    8 
Data from literature evidenced that history of pregnancy complications determines an 9 
increased future cardiovascular risk (18, 19); because of its unique cardiovascular and 10 
metabolic stress, pregnancy permits to estimate a woman’s lifetime risk. Women who failed 11 
this stress test by experiencing placental disorders have an increased future cardiovascular 12 
risk, possibly unmasking early or pre-existing endothelial dysfunction and vascular disease 13 
(20); to date, a history of pregnancy complications entered as major risk factor for CVD in the 14 
AHA/ASA guidelines (3, 4). 15 
Lp(a) represents a well known marker of cardiovascular disease (21-23), and it may also be 16 
used in risk assessment of subjects in the general population, particularly in intermediate-risk 17 
groups (24).  During the last years advances have been achieved in understanding its 18 
pathophysiological role (9-11). Elevated Lp(a) concentrations can increase the risk of CVD 19 
mainly through a prothrombotic/anti-fibrinolytic effects, as apo(a) element possesses 20 
structural homology with plasminogen, and accelerated atherogenesis as a result of intimal 21 
deposition of Lp(a) cholesterol. Interestingly, plasma levels of Lp(a) are similar in both men 22 
and women, nevertheless at similarly high levels of plasma Lp(a), women are more likely to 23 
experience cardiovascular disease than men (25, 26).  24 
Data concerning Lp(a) role in pregnancy complications are not clear-cut. To date, no previous 25 
study investigated Lp(a) levels in women with history of SB; in the present study we evidence 26 
 14 
a role for Lp(a) in modulating SB risk, and this finding may be related to the prothrombotic 1 
and anti-fibrinolytic Lp(a) effects which could lead to impaired placenta perfusion that can 2 
alter oxygen and nutrient supply to the fetus.  3 
We also observed that women with history of preeclampsia exhibited high Lp(a) levels, and 4 
this finding is in keeping with data by Van Pampus MG et al (14), but are at variance with 5 
those from Manten GTR et al. (15); the higher percentage of control women with high Lp(a) 6 
levels (35%) in comparison to that observed in our control group (17%), and the different 7 
assay used for Lp(a) determination, might explain this discrepancy; really, several different 8 
assays are available to measure Lp(a) levels, and the standardization between Lp(a) assay is 9 
still a critical point, which may contribute to affect the comparison among studies (25).  10 
Lp(a) levels are under genetic control, and polymorphisms in LPA gene have been object of 11 
interest, in particular in coronary artery disease (11) and in peripheral artery disease (27), as 12 
well as in healthy subjects (28). In the present study we investigated the role of rs1853021 13 
and rs1800769 LPA gene polymorphisms in modulating Lp(a) levels, and of novelty their role 14 
in affecting placenta mediated pregnancy complications risk. Our data, showed for the first 15 
time a progressive and significant increase of Lp(a) concentrations as LPA allelic burden 16 
increased, and suggest a relationship between unfavorable allelic burden and negative 17 
pregnancy events, in particular SB and PE. Therefore, present findings by evidencing a dose-18 
dependent relationship between LPA variants and both Lp(a) levels and risk of pregnancy 19 
complications, might support the association between Lp(a) elevated plasma level and 20 
negative pregnancy outcomes.  21 
Patients are following up and these results will allow us to identify women who will early 22 
experience atherothrombotic disease. Limitation of our study is the lack of information 23 
concerning KIV repeat number, which better determines Lp(a) concentrations; really, we are 24 
aware that the two polymorphisms investigated in the present study have a relatively small 25 
 15 
influence on Lp(a) levels; nevertheless we selected these two functional polymorphisms based 1 
on others and our previous study (28, 29). Our is a follow-up referral Center, at which the 2 
most severely affected women as well as healthy women, who referred for other CVD risk 3 
factors, would attend, thus representing a further limitation.  4 
Finally, the Lp(a) concentrations evaluated may be related to unresolved pregnancy effects as 5 
the measure were made in specimens collected between 12 to 25 weeks after delivery; 6 
pregnancy related changes may be not resolved until 6 months post-partum, nevertheless it is 7 
well know that Lp(a) increased until 35 weeks of gestation, subsequently decreased slightly 8 
until delivery, and fell to values below early pregnancy concentrations thereafter (30). 9 
Our findings highlight the role of Lp(a) in modulating SB, and confirm the relationship 10 
between Lp(a) and PE risk; interestingly, by analyzing Lp(a) concentrations as the primary 11 
outcome, we provided evidence that a history of both SB and PE influenced Lp(a) 12 
concentrations, thus strengthening the relationship between this atherothrombotic marker and 13 
negative pregnancy outcomes. 14 
 15 
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Legends to figures: 1 
 2 
Supplemental Figure  1. Flow chart  3 
 4 
Figure  1. Lp(a) levels according to each placenta mediated pregnancy complications. 5 
SGA=small for gestational age neonates, PE= preeclampsia, SB=stillbirth, CNTRL=Controls.  6 
 7 
Figure  2.  Lp(a) concentrations according to LPA gene unfavourable alleles burden. 8 
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Table 1. Demographic and clinical characteristics of the study population. 1 
 Patients (n=360) Controls (n=270) p 
Age^ 35 (19-49) 34 (22-40) 0.7 
Pregnancy Complications    
Stillbirth 121 (33.6%) -  
Preeclampsia 154 (42.8%) -  
Small for gestational age neonate 85 (23.6%) -  
CV Risk Factors    
Smoking habits, n(%) 59 (16.4%) 46 (17.0%) 0.8 
Hypertension, n(%) 36 (10.0%) 7 (2.6%) 0.0003 
BMI>25 kg/m2 76 (21.0%) 38 (14.1%) 0.02 
Dyslipidemia, n(%) 66 (18.3%) 15 (5.6%) <0.0001 
Total-C, mg/dL § 204.3 ± 51.0 187.4 ± 37.0 0.003 
LDL-C, mg/dL  § 115.6 ± 33.9 102.4 ± 31.6 <0.0001 
HDL-C, mg/dL § 62.4 ± 18.0 67.4 ± 14.7 0.002 
TG, mg/dL § 114.8 ± 53.2 88.9 ± 48.8 0.008 
Lp(a) mg/L^ 285.9 (236.5-335.4) 185.1 (159.4-210.9) 0.03 
Lp(a)>300 mg/L 115 (31.9%) 46 (17.1%) <0.0001 
Family history of  CVD, n (%) 96 (26.6%) 27 (10%) <0.0001 
 2 
§ media ± DS;  ^ geometric mean (range); Total-C= total cholesterol; LDL-C= LDL cholesterol; HDL-C= HDL 3 
cholesterol; TG= Triglycerides; CVD=cardiovascular disease. 4 
 5 
 18 
 
 
 
Table 2.   Logistic regression analyses on the association between Lp(a) levels and placenta 
mediated pregnancy complications.  
 
 
 
 
 
 
 
PMPC=placenta mediated pregnancy complication. Model 1: Adjusted for age and family history of 
cardiovascular disease. Model 2: Adjusted for age, family history of cardiovascular disease, hypertension, 
dyslipidemia, smoking habit, BMI>25 Kg/m2, and timing form delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Univariate Analysis Multivariate Analysis 
(Model 1) 
Multivariate Analysis 
(Model 2) 
 OR (CI 95%) p OR (CI 95%) p OR (CI 95%) p 
PMPC (n=360) 1.93 (1.20-3.09) 0.006 1.75 (1.08-2.82) 0.02 1.70 (1.02-2.90) 0.04 
Stillbirth (n=121) 2.55 (1.29-5.05) 0.007 2.36 (1.19-4.66) 0.013 2.30 (1.10-4.81) 0.02 
Preeclampsia (n=154) 2.43 (1.23-4.78) 0.01 2.19 (1.07-4.47) 0.03 2.37 (1.12-4.99) 0.02 
Small for gestational age neonate 
(n=85) 
0.98 (0.38-2.52) 0.9 -  -  
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